{"product_id":"rmd-vrio-analysis","title":"ResMed Inc. (RMD): VRIO Analysis [June-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eThis ready-made VRIO Analysis gives you a clear, research-based view of how ResMed Inc. builds sustained advantage through brand trust, FDA-cleared AI-enabled product innovation, a sticky installed base, connected-care data, MatrixCare and Brightree software, a \u003cstrong\u003e140-country\u003c\/strong\u003e distribution network, and strong regulatory and capital resources. It shows you how Value, Rarity, Inimitability, and Organization work across \u003cstrong\u003eJune 2026\u003c\/strong\u003e capabilities, making it a practical study aid for essays, case studies, presentations, and business research.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - VRIO Analysis: First Core Capabilities \/ Resources: Brand value and clinical credibility\n\u003c\/h2\u003e\n\u003ch3\u003eBrand value and clinical credibility\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e fiscal 2024 revenue, \u003cstrong\u003e1989\u003c\/strong\u003e founding year, and sales in \u003cstrong\u003e140+\u003c\/strong\u003e countries show a brand asset that supports prescriber trust, patient adherence, and premium positioning.\u003c\/p\u003e\n\u003cp\u003eThat mix is rare in medical devices because clinical credibility and consumer awareness usually take \u003cstrong\u003e35\u003c\/strong\u003e years of operating history to build.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO test\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eAnalytical effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e fiscal 2024 revenue\u003c\/td\u003e\n\u003ctd\u003eSupports demand, premium pricing, and repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e140+\u003c\/strong\u003e countries; \u003cstrong\u003e1989\u003c\/strong\u003e founding year\u003c\/td\u003e\n\u003ctd\u003eGlobal recognition plus long clinical history is uncommon\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35\u003c\/strong\u003e years of brand building by 2024\u003c\/td\u003e\n\u003ctd\u003eTrust, outcomes evidence, and channel relationships are hard to copy quickly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eMarketing, evidence generation, sales, and product strategy aligned across sleep and respiratory care\u003c\/td\u003e\n\u003ctd\u003eConverts credibility into commercial results\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eBrand and clinical credibility remain difficult to replicate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e revenue supports value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e140+\u003c\/strong\u003e countries support rarity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e35\u003c\/strong\u003e years support inimitability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - VRIO Analysis: Second Core Capabilities \/ Resources: Intellectual property and AI-enabled product innovation\n\u003c\/h2\u003e\n\u003cp\u003eResMed’s IP and AI-enabled product innovation support a business that reported \u003cstrong\u003e$4.69 billion\u003c\/strong\u003e in revenue for the fiscal year ended June 30, 2024, with distribution in \u003cstrong\u003e140+\u003c\/strong\u003e countries.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO item\u003c\/th\u003e\n    \u003cth\u003eReal-life number\u003c\/th\u003e\n    \u003cth\u003eChapter relevance\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFiscal 2024 revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAirSense 11 launch year\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2021\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eAI-enabled product innovation\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCountries served\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e140+\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eOrganization and commercialization reach\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFiscal year end\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLatest reported period\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAirSense 11 sits inside a \u003cstrong\u003e$4.69 billion\u003c\/strong\u003e FY2024 revenue base.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eAirSense 11 launched in \u003cstrong\u003e2021\u003c\/strong\u003e; FDA-cleared AI-enabled comfort personalization in CPAP is uncommon.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003ePatent protection, regulatory clearance, algorithms, and clinical validation create barriers that are harder to copy than a standard device launch.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eResMed operates in \u003cstrong\u003e140+\u003c\/strong\u003e countries and converted this capability set into \u003cstrong\u003e$4.69 billion\u003c\/strong\u003e of FY2024 revenue.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e2021\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e140+\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - VRIO Analysis: Third Core Capabilities \/ Resources: Installed base and recurring consumables ecosystem\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e FY2024 revenue and \u003cstrong\u003e58%\u003c\/strong\u003e FY2024 gross margin.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO point\u003c\/th\u003e\n\u003cth\u003eReal-life number\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e58%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries served\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 140\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent company disclosure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMore than 140\u003c\/strong\u003e countries served\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e revenue base\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e58%\u003c\/strong\u003e gross margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e140+\u003c\/strong\u003e country reach and a \u003cstrong\u003e$4.69 billion\u003c\/strong\u003e revenue base are hard to match quickly.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e58%\u003c\/strong\u003e gross margin supports monetization of repeat consumables sales.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - VRIO Analysis: Fourth Core Capabilities \/ Resources: Connected-care data platform and digital ecosystem\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eResMed's connected-care platform links more than \u003cstrong\u003e23 million\u003c\/strong\u003e cloud-connected devices and supports remote monitoring, adherence optimization, cross-sell, and clinical decision support. Fiscal 2024 revenue was \u003cstrong\u003e$4.69 billion\u003c\/strong\u003e, ending \u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eA connected sleep and breathing data network at this scale is uncommon because it combines device telemetry, patient engagement, and clinician workflows in one system.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eIt is difficult to copy because the platform depends on long data history, installed-device depth, and integrations across hardware and software.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eResMed is organized to use the asset through Smart Comfort, its connected-care strategy, and the Oura partnership.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO test\u003c\/th\u003e\n    \u003cth\u003eReal-life data\u003c\/th\u003e\n    \u003cth\u003eStrategic effect\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e23 million+\u003c\/strong\u003e cloud-connected devices; \u003cstrong\u003e$4.69 billion\u003c\/strong\u003e fiscal 2024 revenue\u003c\/td\u003e\n    \u003ctd\u003eSupports monitoring, adherence, and commercial expansion\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eLarge-scale connected sleep data and device integration\u003c\/td\u003e\n    \u003ctd\u003eUncommon position in the market\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eLong data history and integrated ecosystem\u003c\/td\u003e\n    \u003ctd\u003eHigh barrier to replication\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eSmart Comfort, connected-care strategy, Oura partnership\u003c\/td\u003e\n    \u003ctd\u003eSupports monetization and product linkage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003eData network and workflow lock-in\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e23 million+\u003c\/strong\u003e cloud-connected devices\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e fiscal 2024 revenue\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e fiscal year-end\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - VRIO Analysis: Fifth Core Capabilities \/ Resources: Out-of-hospital software franchises\u003c\/h2\u003e\n\u003cp\u003eResMed Inc. built this capability through \u003cstrong\u003e2\u003c\/strong\u003e major software franchises, Brightree in \u003cstrong\u003e2016\u003c\/strong\u003e for \u003cstrong\u003e$800 million\u003c\/strong\u003e and MatrixCare in \u003cstrong\u003e2018\u003c\/strong\u003e for \u003cstrong\u003e$750 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThese out-of-hospital software assets extend ResMed Inc. beyond devices into workflow software for home and post-acute care. The $800 million and $750 million acquisitions show that management assigned real capital to this layer of the business.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eBroad software coverage across home medical equipment, home health, hospice, and senior care is not common. Owning \u003cstrong\u003e2\u003c\/strong\u003e embedded platforms in these settings is a rarer position than selling stand-alone devices.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003eReplicating these franchises would require the same mix of care-setting expertise, installed workflows, and switching costs built over \u003cstrong\u003e2\u003c\/strong\u003e acquisitions and multiple years of integration. That makes direct copying difficult.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eResMed Inc. has organized these assets as core to its \u003cstrong\u003e2030\u003c\/strong\u003e strategy, with MatrixCare and Brightree positioned inside the software portfolio rather than as side businesses.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO factor\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eBrightree: \u003cstrong\u003e$800 million\u003c\/strong\u003e in \u003cstrong\u003e2016\u003c\/strong\u003e; MatrixCare: \u003cstrong\u003e$750 million\u003c\/strong\u003e in \u003cstrong\u003e2018\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMoves ResMed Inc. into higher-margin software\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e major out-of-hospital software franchises\u003c\/td\u003e\n\u003ctd\u003eBroad embedded coverage is uncommon\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e integrated platforms across care settings\u003c\/td\u003e\n\u003ctd\u003eSwitching costs and workflow depth raise barriers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2030\u003c\/strong\u003e strategy\u003c\/td\u003e\n\u003ctd\u003eManagement has aligned the assets with long-term strategy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eValue, rarity, and difficult imitation support durability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$800 million\u003c\/strong\u003e: Brightree acquisition price\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$750 million\u003c\/strong\u003e: MatrixCare acquisition price\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2016\u003c\/strong\u003e: Brightree acquisition year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2018\u003c\/strong\u003e: MatrixCare acquisition year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e: core out-of-hospital software franchises\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2030\u003c\/strong\u003e: strategy horizon\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - VRIO Analysis: Sixth Core Capabilities \/ Resources: Global distribution and supply chain network\u003c\/h2\u003e\n\u003cp\u003eGlobal distribution across \u003cstrong\u003e140\u003c\/strong\u003e countries supports delivery speed, service reliability, and margin efficiency. The advantage is real, but it is temporary because large-scale medical-device logistics can be built over time.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e140\u003c\/strong\u003e-country reach supports broad product availability, faster delivery, and steadier service levels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003e140\u003c\/strong\u003e countries\u003c\/li\u003e\n  \u003cli\u003eService reliability\u003c\/li\u003e\n  \u003cli\u003eMargin efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eGlobal medical-device distribution at this scale is moderately rare.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003eHard to copy because it needs capital, time, supplier depth, and operational discipline.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe Indiana distribution center and existing operations support execution.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO element\u003c\/th\u003e\n    \u003cth\u003eReal-life data point\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e140\u003c\/strong\u003e countries\u003c\/td\u003e\n    \u003ctd\u003eSupports reach and delivery speed\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eGlobal medical-device logistics at scale\u003c\/td\u003e\n    \u003ctd\u003eModerately rare\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eCapital, time, supplier depth, operational discipline\u003c\/td\u003e\n    \u003ctd\u003eDifficult to imitate\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eIndiana distribution center\u003c\/td\u003e\n    \u003ctd\u003eExecution support\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eCopyable over time\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - VRIO Analysis: Seventh Core Capabilities \/ Resources: Regulatory, quality, and compliance expertise\n\u003c\/h2\u003e\n\u003cp\u003eResMed's regulatory, quality, and compliance capability is \u003cstrong\u003evaluable\u003c\/strong\u003e, \u003cstrong\u003erare\u003c\/strong\u003e, \u003cstrong\u003edifficult to imitate\u003c\/strong\u003e, and \u003cstrong\u003ewell organized\u003c\/strong\u003e, so it supports a \u003cstrong\u003esustained\u003c\/strong\u003e competitive advantage.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eResMed sells in more than \u003cstrong\u003e140\u003c\/strong\u003e countries and operates under regulated pathways such as \u003cstrong\u003eFDA 510(k)\u003c\/strong\u003e, \u003cstrong\u003e21 CFR Part 820\u003c\/strong\u003e, \u003cstrong\u003eISO 13485:2016\u003c\/strong\u003e, and \u003cstrong\u003eEU MDR 2017\/745\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e140+\u003c\/strong\u003e country access depends on compliance strength.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e510(k)\u003c\/strong\u003e and quality-system controls reduce delay and market-entry risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eStrong execution across multiple medical-device regimes is uncommon because each market adds its own documentation, audit, and post-market rules.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThis capability is hard to copy because it depends on years of filings, audits, monitoring, and institutional quality culture rather than a single process.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eResMed's global quality and compliance systems are built to support ongoing access across a \u003cstrong\u003e140+\u003c\/strong\u003e country footprint.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO test\u003c\/td\u003e\n\u003ctd\u003eNumeric or regulatory evidence\u003c\/td\u003e\n\u003ctd\u003eImplication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e140+\u003c\/strong\u003e countries; \u003cstrong\u003e510(k)\u003c\/strong\u003e; \u003cstrong\u003e21 CFR Part 820\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMarket access and lower compliance delay risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eISO 13485:2016\u003c\/strong\u003e; \u003cstrong\u003eEU MDR 2017\/745\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFewer peers match the same execution breadth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eRepeated audits, filings, and monitoring\u003c\/td\u003e\n\u003ctd\u003eHard to duplicate quickly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eGlobal compliance systems across \u003cstrong\u003e140+\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eCapability is embedded in operations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - VRIO Analysis: Eight Core Capabilities \/ Resources: Financial strength and capital allocation\u003c\/h2\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eFY2024 operating cash flow\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eFY2024 gross margin\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e59.9%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eLarge-peer scale\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eLarge-firm cash generation\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eShare repurchases\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$1.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eDividends\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$0.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eVRIO result\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e59.9%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003e$4.69 billion\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e59.9%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003e$1.0 billion\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e$0.3 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eTemporary\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - VRIO Analysis: Ninth Core Capabilities \/ Resources: Strategic partnerships, M\u0026amp;A integration, and leadership bench\n\u003c\/h2\u003e\n\u003cp\u003eResMed's strategic partnerships, M\u0026amp;A integration, and leadership continuity are supported by \u003cstrong\u003e1989\u003c\/strong\u003e founding history, \u003cstrong\u003e2013\u003c\/strong\u003e CEO continuity, and \u003cstrong\u003e$4.7 billion\u003c\/strong\u003e FY2024 revenue.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThese capabilities help ResMed expand reach, absorb acquisitions, and maintain execution through leadership transitions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFY2024 revenue:\u003c\/strong\u003e \u003cstrong\u003e$4.7 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCEO tenure:\u003c\/strong\u003e since \u003cstrong\u003e2013\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOperating history:\u003c\/strong\u003e \u003cstrong\u003e35\u003c\/strong\u003e years from \u003cstrong\u003e1989\u003c\/strong\u003e to \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eHigh-trust partnerships and disciplined integration are not common, especially at a company with \u003cstrong\u003e$4.7 billion\u003c\/strong\u003e in FY2024 revenue.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHard to copy because trust, deal discipline, and leadership continuity built over \u003cstrong\u003e11\u003c\/strong\u003e years of the same CEO are difficult to replicate.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eResMed is organized to use these resources through sustained leadership continuity and scale.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eReal-life number\u003c\/td\u003e\n    \u003ctd\u003eVRIO relevance\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFounded\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1989\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e35\u003c\/strong\u003e years of operating history by \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCEO continuity\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2013\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e11\u003c\/strong\u003e years of leadership continuity by \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$4.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eScale to support partnerships and integration\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQ4 FY2024 revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$1.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eShows operating scale in the latest quarter\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516242485397,"sku":"rmd-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/rmd-vrio-analysis.png?v=1740210903","url":"https:\/\/dcf-model.com\/fr\/products\/rmd-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}